TOP2B (DNA topoisomerase 2-beta) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Lung cancer, Neuroendocrine tumours, Breast cancer and 1 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Key decatenating enzyme that alters DNA topology by binding to two double-stranded DNA molecules, generating a double-stranded break in one of the strands, passing the intact strand through the broken strand, and religating the broken strand. Plays a role in B-cell differentiation. Location: Nucleus, nucleolus; Nucleus, nucleoplasm; Nucleus (UniProt). Locus 3p24.2 (HGNC).
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"TOP2B" OR ABSTRACT:"TOP2B" OR TITLE:"DNA topoisomerase II beta" OR ABSTRACT:"DNA topoisomerase II beta" OR TITLE:"DNA topoisomerase 2-beta" OR ABSTRACT:"DNA topoisomerase 2-beta" OR TITLE:"top2beta" OR ABSTRACT:"top2beta" OR TITLE:"TOPIIB" OR ABSTRACT:"TOPIIB") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TOP2B, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/top2b.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/top2b.json. Licence CC BY-NC 4.0.